Eshoo Amendment Would Allow Substitution Of Biosimilars Without Health Care Provider Okay
This article was originally published in The Pink Sheet Daily
Executive Summary
Few differences with Senate HELP bill remain, as House Democrat adopts that panel's language on products available for data exclusivity.
You may also be interested in...
Road To Biosimilar Interchangeability Could Be Through Market Experience
Demonstrating that a biosimilar is interchangeable with its reference product may be a subject for post-market studies rather than clinical trials, according to Kathleen Sanzo, partner at Morgan, Lewis and Bockius
Road To Biosimilar Interchangeability Could Be Through Market Experience
Demonstrating that a biosimilar is interchangeable with its reference product may be a subject for post-market studies rather than clinical trials, according to Kathleen Sanzo, partner at Morgan, Lewis and Bockius
Follow-on Biologics Go Back To The Future: Senate Cmte. Endorses 12 Years of Brand Exclusivity
Hatch/Enzi/Hagan amendment retains the number from last year's bill, but a fight on floor seems possible.